Drug interactions and pharmacokinetics

Drug interactions and pharmacokinetics features

• 

  One in five Kenyan patients suffers major interactions between HIV drugs and other medicines

  Nearly 20% of patients in an HV treatment programme in Kenya have suffered major interactions between their HIV drugs and other prescribed medicines, a study...

  From:  HIV & AIDS treatment in practice

Drug interactions and pharmacokinetics news from aidsmap

• Dosing of key TB drug rifampicin could go higher

  Rifampicin, a key drug in tuberculosis (TB) treatment, can be tolerated at much higher doses than used in current clinical practice – suggesting that much higher drug levels may lead to a more rapid treatment response, allowing the treatment ...

  07 March 2013 | Keith Alcorn

• Combined oral contraception has less effect on nevirapine than efavirenz levels

  HIV therapy based on efavirenz may less suitable for women taking combined oral contraception due to greater reductions in efavirenz levels and a higher frequency of hormonal contraception side effects, according to research conducted in Thailand and ...

  21 December 2012 | Michael Carter

• CNS symptoms common in people taking raltegravir

  Approximately 10% of patients taking the antiretroviral drug raltegravir (Isentress) develop central nervous system (CNS) side-effects, research published in the online edition of AIDS shows. The development of CNS side-effects was associated with the co-administration of tenofovir (Viread, also in Truvada, ...

  10 October 2012 | Michael Carter

• Raltegravir 800mg twice daily appears a good alternative to efavirenz for HIV-TB treatment

  Raltegravir seems to be a suitable alternative to efavirenz for HIV-TB co-infected patients while receiving TB treatment, according to 24-week results of the ANRS 12 180 REFLATE study presented at the Nineteenth International AIDS Conference (AIDS 2012) in Washington ...

  31 July 2012 | Lesley Odendal

• Cobicistat matches ritonavir as atazanavir booster

  The new boosting agent cobicistat works as well as ritonavir (Norvir) as a pharmaco-enhancer or booster for the first-line protease inhibitor atazanavir (Reyataz) at 48 weeks, according to a report presented last week at the 19th International AIDS Conference in ...

  30 July 2012 | Liz Highleyman

• Co-administration of rifampicin and efavirenz does not reduce efavirenz concentrations or efficacy

  Standard dosing of efavirenz, that was not adjusted for patient weight, resulted in therapeutic efavirenz concentrations and excellent virological outcomes in patients coinfected with TB and HIV who were also taking a rifampicin-containing TB treatment, according to results from the ...

  24 July 2012 | Lesley Odendal

• No evidence of an interaction between abacavir and ribavirin

  There is no evidence of an interaction between the anti-HIV drug abacavir and the anti-hepatitis C agent ribavirin, investigators report in the online edition of AIDS. Some earlier research reported poorer hepatitis C treatment outcomes in co-infected patients whose antiretroviral regimens ...

  17 July 2012 | Michael Carter

• Study shows that use of darunavir/ritonavir and etravirine in HIV treatment as a prevention method is biologically plausible

  A pharmacokinetic study suggests that ritonavir-boosted darunavir (Prezista) and etravirine (Intelence) achieve high concentrations in semen and rectal tissue, and could therefore help avert HIV transmission and infection, especially in gay men. Concentrations of these antiretrovirals were monitored over an eight-day ...

  13 June 2012 | Michael Carter

• Studies look at interactions between new hepatitis C drugs and HIV antiretrovirals

  Drug-drug interactions between direct-acting antiviral agents for hepatitis C and some antiretroviral medications used to treat HIV are common, but are often modest and can be managed with dose adjustments when treating people with HIV/HCV coinfection, researchers reported at ...

  14 March 2012 | Liz Highleyman

• Lopinavir/ritonavir cuts malaria risk in children with HIV

  HIV-infected children in Tororo, Uganda, an area of high malaria transmission, on a lopinavir/ritonavir (LPV/r, or Kaletra)-based antiretroviral (ART) regimen had a significantly lower risk of getting malaria, compared to those on a non-nucleoside reverse transcriptase (NNRTI)-based regimen, researchers reported ...

  07 March 2012 | Carole Leach-Lemens

More news

Drug interactions and pharmacokinetics news selected from other sources

• Prezista (darunavir) label change - drug interaction information

  The FDA recently approved changes to the Prezista (darunavir) label to reflect drug interaction information with artemether/lumefantrine. The specific changes are outlined below.

  02 March 2013 | US Food and Drug Administration

• Updated HIV Treatment Guidelines Include Stronger Recommendation for Acute Infection

  Among the key changes are additional information about the most recently approved antiretroviral agents and a recommendation that newly infected people with HIV should be offered combination ART. The guidelines continue to recommend treatment for all people with HIV, both to reduce the risk of disease progressionand for the prevention of HIV transmission.

  15 February 2013 | HIVandHepatitis.com

• Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

  A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

  15 February 2013 | CATIE

• Updated U.S. DHHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents

  New recommendations on drug-resistance testing, genotypic tropism assays, starting treatment, acute infection, pregnancy and interactions.

  15 February 2013 | AIDSinfo

• Certain Meds Mixed With Grapefruit Juice Can Be a Fatal Cocktail

  The scientist who discovered that grapefruit can alter  drug levels in the body has released an updated list of 85 medications that may cause such reactions, in order to reflect releases of new medications over the past four years.

  21 December 2012 | AIDSMeds

• Mistakes are still commonly made in prescriptions of antiretroviral medications

  Research presented at IDWeek 2012- concludes that despite advances in electronic medical records, mistakes are still commonly made in the prescription of antiretroviral medications for hospitalized HIV-positive patients. At the same time, a trio of studies suggests however, that electronic records in combination with increased clinical education can help to greatly decrease medical errors.

  22 October 2012 | News Medical

• Tuberculosis: Combined wisdom

  Buried in the HIV frenzy at the International AIDS Conference was a rather important announcement for another blight, tuberculosis.

  26 July 2012 | The Economist

• Efavirenz Works in Kids with Both HIV and TB

  Children co-infected with HIV and tuberculosis appear to suppress both infections when treated with standard TB regimens and an efavirenz-based HIV regimen, researchers said here at the International AIDS Conference.

  25 July 2012 | MedPage Today HIV/AIDS

• Similar Efficacy, Side Effects in Study of Gilead Booster Cobicistat and Norvir

  Compared with Norvir (ritonavir), people living with HIV using Gilead Sciences’ novel boosting agent cobicistat were just as likely to see their viral loads drop to undetectable levels and no more likely to discontinue therapy due to side effects, according to preliminary results from a Phase III study comparing both drugs in combination with Reyataz (atazanavir) and Truvada (tenofovir plus emtricitabine).

  25 July 2012 | AIDSMeds

• UCSF/SFGH Researchers Call for Change in New FDA Recommendation on HIV and TB Drug Doses

  In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB). Now, a new analysis by the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH) suggests this recommended dose adjustment may not be necessary, particularly in non-Caucasian populations.

  24 July 2012 | USCF News Center

More news